At a glance
For Queensland residents admitted to Queensland public and private hospitals:
- In 2020–21 there were 167,675 hospitalisations among Queensland residents that were potentially preventable—5.9% of all hospitalisations by Queensland residents within the state.
- Adults 85 and older experienced the highest rate of potentially preventable hospitalisations in 2020–21 (192.6 per 1,000 persons)—the majority for chronic conditions such as diabetes complications, congestive cardiac failure, and COPD.
- Standardised rates for vaccine preventable potentially preventable hospitalisations declined 3-fold from 2019–20 to 2020–21—in large part due to reduced flu-related hospitalisations resulting from COVID-19 public safety measures.
- Potentially preventable hospitalisation rates varied by remoteness and socioeconomic status—standardised rates were:
- 2 times higher for those living in remote and very remote areas compared to those living in major cities (55.7 and 27.5 per 1,000 persons, respectively)
- 87% higher for those living in socioeconomically disadvantaged areas compared to those living in advantaged areas (40.6 and 21.7 per 1,000 persons, respectively).
Introduction
A subset of hospitalisations are considered potentially preventable and are collectively known as selected potentially preventable hospitalisations (PPHs). Under the National Healthcare Agreement, PPHs are defined as hospitalisations from conditions that could have been prevented through the provision of appropriate individualised preventative health interventions and early disease management, usually delivered in a primary health care and community-based care settings.1 They are used as measures of system performance in Australia and internationally.2
Potentially preventable hospitalisations are identified from diagnoses recorded in hospital admission data. There are three broad categories: chronic, acute, and vaccine-preventable, consisting of 22 specific health conditions.
Potentially preventable hospitalisations by category
In 2020–21, Queensland residents had 167,675 potentially preventable hospitalisations (PPH) episodes of care in Queensland hospitals.3 These were 5.9% of all hospitalisations.
- The Queensland PPH rate was higher than the national rate and ranked 7th of the jurisdictions.4
- Of the three broad categories, acute conditions had the highest standardised rate (16.3 per 1,000 persons), followed by chronic conditions (12.7 per 1,000 persons) (Figure 1).
Figure 1: Selected potentially preventable hospitalisations by category for Queensland residents, 2020–21
Condition | Sex | Type | Rate per 1,000 |
---|---|---|---|
Total acute | Females | Crude Rate | 18.2 |
Total acute | Females | Age Standardised Rate | 17.4 |
Total acute | Males | Crude Rate | 15.8 |
Total acute | Males | Age Standardised Rate | 15.3 |
Total acute | Persons | Crude Rate | 17.0 |
Total acute | Persons | Age Standardised Rate | 16.3 |
Total chronic | Females | Crude Rate | 14.8 |
Total chronic | Females | Age Standardised Rate | 12.6 |
Total chronic | Males | Crude Rate | 14.3 |
Total chronic | Males | Age Standardised Rate | 12.8 |
Total chronic | Persons | Crude Rate | 14.6 |
Total chronic | Persons | Age Standardised Rate | 12.7 |
Total potentially preventable hospitalisations | Females | Crude Rate | 33.7 |
Total potentially preventable hospitalisations | Females | Age Standardised Rate | 30.7 |
Total potentially preventable hospitalisations | Males | Crude Rate | 31.0 |
Total potentially preventable hospitalisations | Males | Age Standardised Rate | 28.9 |
Total potentially preventable hospitalisations | Persons | Crude Rate | 32.4 |
Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 29.8 |
Total vaccine preventable | Females | Crude Rate | 0.9 |
Total vaccine preventable | Females | Age Standardised Rate | 0.8 |
Total vaccine preventable | Males | Crude Rate | 1.0 |
Total vaccine preventable | Males | Age Standardised Rate | 0.9 |
Total vaccine preventable | Persons | Crude Rate | 0.9 |
Total vaccine preventable | Persons | Age Standardised Rate | 0.9 |
Age groups
PPHs vary by age. For example, older people are more likely to have chronic conditions that can lead to hospitalisations, while children are more likely to be hospitalised for acute conditions.
In 2020–21:
- Adults 85 years and older had the highest PPH rate (192.6 per 1,000 persons), with the majority for chronic conditions such as chronic obstructive pulmonary disease (COPD).
A few conditions, such as dental and asthma, had higher rates for children (Figure 2 and Supplemental Figure S1 under Additional information).
Figure 2: Selected potentially preventable hospitalisations in Queensland by category and age, 2020–21
PPH category | Condition | Age Group | Age-specific rates per 1,000 |
---|---|---|---|
Acute | Total acute | 0 to 4 | 31.5 |
Acute | Total acute | 5 to 9 | 15.0 |
Acute | Total acute | 10 to 14 | 6.5 |
Acute | Total acute | 15 to 19 | 13.2 |
Acute | Total acute | 20 to 24 | 14.3 |
Acute | Total acute | 25 to 29 | 11.8 |
Acute | Total acute | 30 to 34 | 11.1 |
Acute | Total acute | 35 to 39 | 11.3 |
Acute | Total acute | 40 to 44 | 11.4 |
Acute | Total acute | 45 to 49 | 12.0 |
Acute | Total acute | 50 to 54 | 13.3 |
Acute | Total acute | 55 to 59 | 13.9 |
Acute | Total acute | 60 to 64 | 16.1 |
Acute | Total acute | 65 to 69 | 19.2 |
Acute | Total acute | 70 to 74 | 24.6 |
Acute | Total acute | 75 to 79 | 34.5 |
Acute | Total acute | 80 to 84 | 48.9 |
Acute | Total acute | 85 plus | 79.1 |
Chronic | Angina | 0 to 4 | 0.0 |
Chronic | Angina | 5 to 9 | 0.0 |
Chronic | Angina | 10 to 14 | 0.0 |
Chronic | Angina | 15 to 19 | 0.0 |
Chronic | Angina | 20 to 24 | 0.0 |
Chronic | Angina | 25 to 29 | 0.0 |
Chronic | Angina | 30 to 34 | 0.1 |
Chronic | Angina | 35 to 39 | 0.2 |
Chronic | Angina | 40 to 44 | 0.5 |
Chronic | Angina | 45 to 49 | 0.8 |
Chronic | Angina | 50 to 54 | 1.3 |
Chronic | Angina | 55 to 59 | 2.0 |
Chronic | Angina | 60 to 64 | 2.9 |
Chronic | Angina | 65 to 69 | 3.5 |
Chronic | Angina | 70 to 74 | 4.7 |
Chronic | Angina | 75 to 79 | 6.1 |
Chronic | Angina | 80 to 84 | 7.0 |
Chronic | Angina | 85 plus | 7.8 |
Chronic | Asthma | 0 to 4 | 0.6 |
Chronic | Asthma | 5 to 9 | 3.3 |
Chronic | Asthma | 10 to 14 | 1.2 |
Chronic | Asthma | 15 to 19 | 0.8 |
Chronic | Asthma | 20 to 24 | 0.9 |
Chronic | Asthma | 25 to 29 | 0.8 |
Chronic | Asthma | 30 to 34 | 0.7 |
Chronic | Asthma | 35 to 39 | 0.9 |
Chronic | Asthma | 40 to 44 | 1.0 |
Chronic | Asthma | 45 to 49 | 0.8 |
Chronic | Asthma | 50 to 54 | 1.0 |
Chronic | Asthma | 55 to 59 | 1.0 |
Chronic | Asthma | 60 to 64 | 1.0 |
Chronic | Asthma | 65 to 69 | 1.1 |
Chronic | Asthma | 70 to 74 | 1.3 |
Chronic | Asthma | 75 to 79 | 1.5 |
Chronic | Asthma | 80 to 84 | 1.2 |
Chronic | Asthma | 85 plus | 1.1 |
Chronic | Bronchiectasis | 0 to 4 | 0.3 |
Chronic | Bronchiectasis | 5 to 9 | 0.2 |
Chronic | Bronchiectasis | 10 to 14 | 0.1 |
Chronic | Bronchiectasis | 15 to 19 | 0.1 |
Chronic | Bronchiectasis | 20 to 24 | 0.2 |
Chronic | Bronchiectasis | 25 to 29 | 0.1 |
Chronic | Bronchiectasis | 30 to 34 | 0.1 |
Chronic | Bronchiectasis | 35 to 39 | 0.1 |
Chronic | Bronchiectasis | 40 to 44 | 0.1 |
Chronic | Bronchiectasis | 45 to 49 | 0.1 |
Chronic | Bronchiectasis | 50 to 54 | 0.2 |
Chronic | Bronchiectasis | 55 to 59 | 0.3 |
Chronic | Bronchiectasis | 60 to 64 | 0.3 |
Chronic | Bronchiectasis | 65 to 69 | 0.9 |
Chronic | Bronchiectasis | 70 to 74 | 1.5 |
Chronic | Bronchiectasis | 75 to 79 | 2.4 |
Chronic | Bronchiectasis | 80 to 84 | 3.2 |
Chronic | Bronchiectasis | 85 plus | 2.8 |
Chronic | COPD | 0 to 4 | 0.1 |
Chronic | COPD | 5 to 9 | 0.1 |
Chronic | COPD | 10 to 14 | 0.0 |
Chronic | COPD | 15 to 19 | 0.0 |
Chronic | COPD | 20 to 24 | 0.0 |
Chronic | COPD | 25 to 29 | 0.0 |
Chronic | COPD | 30 to 34 | 0.0 |
Chronic | COPD | 35 to 39 | 0.2 |
Chronic | COPD | 40 to 44 | 0.3 |
Chronic | COPD | 45 to 49 | 0.8 |
Chronic | COPD | 50 to 54 | 1.6 |
Chronic | COPD | 55 to 59 | 3.0 |
Chronic | COPD | 60 to 64 | 5.1 |
Chronic | COPD | 65 to 69 | 6.9 |
Chronic | COPD | 70 to 74 | 11.0 |
Chronic | COPD | 75 to 79 | 15.4 |
Chronic | COPD | 80 to 84 | 17.4 |
Chronic | COPD | 85 plus | 16.2 |
Acute | Cellulitis | 0 to 4 | 2.2 |
Acute | Cellulitis | 5 to 9 | 1.1 |
Acute | Cellulitis | 10 to 14 | 1.0 |
Acute | Cellulitis | 15 to 19 | 1.6 |
Acute | Cellulitis | 20 to 24 | 2.0 |
Acute | Cellulitis | 25 to 29 | 2.2 |
Acute | Cellulitis | 30 to 34 | 2.5 |
Acute | Cellulitis | 35 to 39 | 2.9 |
Acute | Cellulitis | 40 to 44 | 3.2 |
Acute | Cellulitis | 45 to 49 | 3.3 |
Acute | Cellulitis | 50 to 54 | 4.0 |
Acute | Cellulitis | 55 to 59 | 4.0 |
Acute | Cellulitis | 60 to 64 | 4.4 |
Acute | Cellulitis | 65 to 69 | 5.5 |
Acute | Cellulitis | 70 to 74 | 6.9 |
Acute | Cellulitis | 75 to 79 | 10.1 |
Acute | Cellulitis | 80 to 84 | 13.9 |
Acute | Cellulitis | 85 plus | 23.0 |
Chronic | Total chronic | 0 to 4 | 1.6 |
Chronic | Total chronic | 5 to 9 | 4.3 |
Chronic | Total chronic | 10 to 14 | 3.1 |
Chronic | Total chronic | 15 to 19 | 3.4 |
Chronic | Total chronic | 20 to 24 | 3.6 |
Chronic | Total chronic | 25 to 29 | 3.5 |
Chronic | Total chronic | 30 to 34 | 3.8 |
Chronic | Total chronic | 35 to 39 | 5.7 |
Chronic | Total chronic | 40 to 44 | 7.2 |
Chronic | Total chronic | 45 to 49 | 9.1 |
Chronic | Total chronic | 50 to 54 | 11.6 |
Chronic | Total chronic | 55 to 59 | 15.1 |
Chronic | Total chronic | 60 to 64 | 20.4 |
Chronic | Total chronic | 65 to 69 | 28.9 |
Chronic | Total chronic | 70 to 74 | 41.7 |
Chronic | Total chronic | 75 to 79 | 61.6 |
Chronic | Total chronic | 80 to 84 | 82.9 |
Chronic | Total chronic | 85 plus | 112.5 |
Chronic | Congestive cardiac failure | 0 to 4 | 0.1 |
Chronic | Congestive cardiac failure | 5 to 9 | 0.0 |
Chronic | Congestive cardiac failure | 10 to 14 | 0.0 |
Chronic | Congestive cardiac failure | 15 to 19 | 0.0 |
Chronic | Congestive cardiac failure | 20 to 24 | 0.0 |
Chronic | Congestive cardiac failure | 25 to 29 | 0.2 |
Chronic | Congestive cardiac failure | 30 to 34 | 0.1 |
Chronic | Congestive cardiac failure | 35 to 39 | 0.3 |
Chronic | Congestive cardiac failure | 40 to 44 | 0.5 |
Chronic | Congestive cardiac failure | 45 to 49 | 0.5 |
Chronic | Congestive cardiac failure | 50 to 54 | 1.0 |
Chronic | Congestive cardiac failure | 55 to 59 | 1.5 |
Chronic | Congestive cardiac failure | 60 to 64 | 2.2 |
Chronic | Congestive cardiac failure | 65 to 69 | 3.9 |
Chronic | Congestive cardiac failure | 70 to 74 | 6.7 |
Chronic | Congestive cardiac failure | 75 to 79 | 13.0 |
Chronic | Congestive cardiac failure | 80 to 84 | 25.2 |
Chronic | Congestive cardiac failure | 85 plus | 53.8 |
Acute | Convulsions and epilepsy | 0 to 4 | 4.3 |
Acute | Convulsions and epilepsy | 5 to 9 | 1.7 |
Acute | Convulsions and epilepsy | 10 to 14 | 1.3 |
Acute | Convulsions and epilepsy | 15 to 19 | 1.9 |
Acute | Convulsions and epilepsy | 20 to 24 | 2.0 |
Acute | Convulsions and epilepsy | 25 to 29 | 1.6 |
Acute | Convulsions and epilepsy | 30 to 34 | 1.5 |
Acute | Convulsions and epilepsy | 35 to 39 | 1.7 |
Acute | Convulsions and epilepsy | 40 to 44 | 1.4 |
Acute | Convulsions and epilepsy | 45 to 49 | 1.8 |
Acute | Convulsions and epilepsy | 50 to 54 | 1.6 |
Acute | Convulsions and epilepsy | 55 to 59 | 1.7 |
Acute | Convulsions and epilepsy | 60 to 64 | 1.6 |
Acute | Convulsions and epilepsy | 65 to 69 | 1.9 |
Acute | Convulsions and epilepsy | 70 to 74 | 2.0 |
Acute | Convulsions and epilepsy | 75 to 79 | 2.2 |
Acute | Convulsions and epilepsy | 80 to 84 | 2.6 |
Acute | Convulsions and epilepsy | 85 plus | 3.3 |
Acute | Dental conditions | 0 to 4 | 5.4 |
Acute | Dental conditions | 5 to 9 | 9.4 |
Acute | Dental conditions | 10 to 14 | 2.8 |
Acute | Dental conditions | 15 to 19 | 3.9 |
Acute | Dental conditions | 20 to 24 | 4.0 |
Acute | Dental conditions | 25 to 29 | 3.0 |
Acute | Dental conditions | 30 to 34 | 2.7 |
Acute | Dental conditions | 35 to 39 | 2.4 |
Acute | Dental conditions | 40 to 44 | 2.5 |
Acute | Dental conditions | 45 to 49 | 2.8 |
Acute | Dental conditions | 50 to 54 | 3.1 |
Acute | Dental conditions | 55 to 59 | 3.1 |
Acute | Dental conditions | 60 to 64 | 3.5 |
Acute | Dental conditions | 65 to 69 | 3.6 |
Acute | Dental conditions | 70 to 74 | 3.9 |
Acute | Dental conditions | 75 to 79 | 3.6 |
Acute | Dental conditions | 80 to 84 | 3.3 |
Acute | Dental conditions | 85 plus | 3.1 |
Chronic | Diabetes complications | 0 to 4 | 0.2 |
Chronic | Diabetes complications | 5 to 9 | 0.6 |
Chronic | Diabetes complications | 10 to 14 | 1.3 |
Chronic | Diabetes complications | 15 to 19 | 1.4 |
Chronic | Diabetes complications | 20 to 24 | 1.3 |
Chronic | Diabetes complications | 25 to 29 | 1.1 |
Chronic | Diabetes complications | 30 to 34 | 0.9 |
Chronic | Diabetes complications | 35 to 39 | 1.4 |
Chronic | Diabetes complications | 40 to 44 | 1.5 |
Chronic | Diabetes complications | 45 to 49 | 2.2 |
Chronic | Diabetes complications | 50 to 54 | 2.7 |
Chronic | Diabetes complications | 55 to 59 | 3.9 |
Chronic | Diabetes complications | 60 to 64 | 4.2 |
Chronic | Diabetes complications | 65 to 69 | 5.5 |
Chronic | Diabetes complications | 70 to 74 | 6.6 |
Chronic | Diabetes complications | 75 to 79 | 8.0 |
Chronic | Diabetes complications | 80 to 84 | 9.0 |
Chronic | Diabetes complications | 85 plus | 8.1 |
Acute | Ear, nose and throat infections | 0 to 4 | 15.8 |
Acute | Ear, nose and throat infections | 5 to 9 | 1.7 |
Acute | Ear, nose and throat infections | 10 to 14 | 0.7 |
Acute | Ear, nose and throat infections | 15 to 19 | 2.2 |
Acute | Ear, nose and throat infections | 20 to 24 | 1.9 |
Acute | Ear, nose and throat infections | 25 to 29 | 1.3 |
Acute | Ear, nose and throat infections | 30 to 34 | 1.1 |
Acute | Ear, nose and throat infections | 35 to 39 | 1.0 |
Acute | Ear, nose and throat infections | 40 to 44 | 0.8 |
Acute | Ear, nose and throat infections | 45 to 49 | 0.6 |
Acute | Ear, nose and throat infections | 50 to 54 | 0.6 |
Acute | Ear, nose and throat infections | 55 to 59 | 0.6 |
Acute | Ear, nose and throat infections | 60 to 64 | 0.7 |
Acute | Ear, nose and throat infections | 65 to 69 | 0.8 |
Acute | Ear, nose and throat infections | 70 to 74 | 0.7 |
Acute | Ear, nose and throat infections | 75 to 79 | 1.0 |
Acute | Ear, nose and throat infections | 80 to 84 | 1.3 |
Acute | Ear, nose and throat infections | 85 plus | 1.9 |
Acute | Eclampsia | 0 to 4 | 0.0 |
Acute | Eclampsia | 5 to 9 | 0.0 |
Acute | Eclampsia | 10 to 14 | 0.0 |
Acute | Eclampsia | 15 to 19 | 0.0 |
Acute | Eclampsia | 20 to 24 | 0.0 |
Acute | Eclampsia | 25 to 29 | 0.0 |
Acute | Eclampsia | 30 to 34 | 0.0 |
Acute | Eclampsia | 35 to 39 | 0.0 |
Acute | Eclampsia | 40 to 44 | 0.0 |
Acute | Eclampsia | 45 to 49 | 0.0 |
Acute | Eclampsia | 50 to 54 | 0.0 |
Acute | Eclampsia | 55 to 59 | 0.0 |
Acute | Eclampsia | 60 to 64 | 0.0 |
Acute | Eclampsia | 65 to 69 | 0.0 |
Acute | Eclampsia | 70 to 74 | 0.0 |
Acute | Eclampsia | 75 to 79 | 0.0 |
Acute | Eclampsia | 80 to 84 | 0.0 |
Acute | Eclampsia | 85 plus | 0.0 |
Acute | Gangrene | 0 to 4 | 0.1 |
Acute | Gangrene | 5 to 9 | 0.1 |
Acute | Gangrene | 10 to 14 | 0.1 |
Acute | Gangrene | 15 to 19 | 0.2 |
Acute | Gangrene | 20 to 24 | 0.2 |
Acute | Gangrene | 25 to 29 | 0.3 |
Acute | Gangrene | 30 to 34 | 0.4 |
Acute | Gangrene | 35 to 39 | 0.4 |
Acute | Gangrene | 40 to 44 | 0.5 |
Acute | Gangrene | 45 to 49 | 0.6 |
Acute | Gangrene | 50 to 54 | 0.8 |
Acute | Gangrene | 55 to 59 | 0.7 |
Acute | Gangrene | 60 to 64 | 1.0 |
Acute | Gangrene | 65 to 69 | 1.2 |
Acute | Gangrene | 70 to 74 | 1.2 |
Acute | Gangrene | 75 to 79 | 2.0 |
Acute | Gangrene | 80 to 84 | 3.2 |
Acute | Gangrene | 85 plus | 4.7 |
Chronic | Hypertension | 0 to 4 | 0.0 |
Chronic | Hypertension | 5 to 9 | 0.0 |
Chronic | Hypertension | 10 to 14 | 0.0 |
Chronic | Hypertension | 15 to 19 | 0.0 |
Chronic | Hypertension | 20 to 24 | 0.1 |
Chronic | Hypertension | 25 to 29 | 0.1 |
Chronic | Hypertension | 30 to 34 | 0.2 |
Chronic | Hypertension | 35 to 39 | 0.3 |
Chronic | Hypertension | 40 to 44 | 0.5 |
Chronic | Hypertension | 45 to 49 | 0.7 |
Chronic | Hypertension | 50 to 54 | 0.8 |
Chronic | Hypertension | 55 to 59 | 0.9 |
Chronic | Hypertension | 60 to 64 | 1.2 |
Chronic | Hypertension | 65 to 69 | 1.7 |
Chronic | Hypertension | 70 to 74 | 2.5 |
Chronic | Hypertension | 75 to 79 | 3.8 |
Chronic | Hypertension | 80 to 84 | 6.0 |
Chronic | Hypertension | 85 plus | 8.1 |
Chronic | Iron deficiency anaemia | 0 to 4 | 0.3 |
Chronic | Iron deficiency anaemia | 5 to 9 | 0.1 |
Chronic | Iron deficiency anaemia | 10 to 14 | 0.3 |
Chronic | Iron deficiency anaemia | 15 to 19 | 0.9 |
Chronic | Iron deficiency anaemia | 20 to 24 | 1.1 |
Chronic | Iron deficiency anaemia | 25 to 29 | 1.1 |
Chronic | Iron deficiency anaemia | 30 to 34 | 1.7 |
Chronic | Iron deficiency anaemia | 35 to 39 | 2.2 |
Chronic | Iron deficiency anaemia | 40 to 44 | 2.7 |
Chronic | Iron deficiency anaemia | 45 to 49 | 2.9 |
Chronic | Iron deficiency anaemia | 50 to 54 | 2.8 |
Chronic | Iron deficiency anaemia | 55 to 59 | 2.3 |
Chronic | Iron deficiency anaemia | 60 to 64 | 3.0 |
Chronic | Iron deficiency anaemia | 65 to 69 | 4.5 |
Chronic | Iron deficiency anaemia | 70 to 74 | 6.6 |
Chronic | Iron deficiency anaemia | 75 to 79 | 9.7 |
Chronic | Iron deficiency anaemia | 80 to 84 | 12.2 |
Chronic | Iron deficiency anaemia | 85 plus | 13.7 |
Chronic | Nutritional deficiencies | 0 to 4 | 0.1 |
Chronic | Nutritional deficiencies | 5 to 9 | 0.0 |
Chronic | Nutritional deficiencies | 10 to 14 | 0.0 |
Chronic | Nutritional deficiencies | 15 to 19 | 0.1 |
Chronic | Nutritional deficiencies | 20 to 24 | 0.0 |
Chronic | Nutritional deficiencies | 25 to 29 | 0.0 |
Chronic | Nutritional deficiencies | 30 to 34 | 0.0 |
Chronic | Nutritional deficiencies | 35 to 39 | 0.0 |
Chronic | Nutritional deficiencies | 40 to 44 | 0.0 |
Chronic | Nutritional deficiencies | 45 to 49 | 0.0 |
Chronic | Nutritional deficiencies | 50 to 54 | 0.0 |
Chronic | Nutritional deficiencies | 55 to 59 | 0.1 |
Chronic | Nutritional deficiencies | 60 to 64 | 0.1 |
Chronic | Nutritional deficiencies | 65 to 69 | 0.2 |
Chronic | Nutritional deficiencies | 70 to 74 | 0.1 |
Chronic | Nutritional deficiencies | 75 to 79 | 0.1 |
Chronic | Nutritional deficiencies | 80 to 84 | 0.2 |
Chronic | Nutritional deficiencies | 85 plus | 0.2 |
Vaccine preventable | Other vaccine-preventable conditions | 0 to 4 | 0.2 |
Vaccine preventable | Other vaccine-preventable conditions | 5 to 9 | 0.0 |
Vaccine preventable | Other vaccine-preventable conditions | 10 to 14 | 0.0 |
Vaccine preventable | Other vaccine-preventable conditions | 15 to 19 | 0.1 |
Vaccine preventable | Other vaccine-preventable conditions | 20 to 24 | 0.2 |
Vaccine preventable | Other vaccine-preventable conditions | 25 to 29 | 0.3 |
Vaccine preventable | Other vaccine-preventable conditions | 30 to 34 | 0.6 |
Vaccine preventable | Other vaccine-preventable conditions | 35 to 39 | 0.9 |
Vaccine preventable | Other vaccine-preventable conditions | 40 to 44 | 1.0 |
Vaccine preventable | Other vaccine-preventable conditions | 45 to 49 | 1.1 |
Vaccine preventable | Other vaccine-preventable conditions | 50 to 54 | 1.3 |
Vaccine preventable | Other vaccine-preventable conditions | 55 to 59 | 1.7 |
Vaccine preventable | Other vaccine-preventable conditions | 60 to 64 | 1.8 |
Vaccine preventable | Other vaccine-preventable conditions | 65 to 69 | 2.0 |
Vaccine preventable | Other vaccine-preventable conditions | 70 to 74 | 1.6 |
Vaccine preventable | Other vaccine-preventable conditions | 75 to 79 | 1.5 |
Vaccine preventable | Other vaccine-preventable conditions | 80 to 84 | 1.0 |
Vaccine preventable | Other vaccine-preventable conditions | 85 plus | 0.8 |
Acute | Pelvic inflammatory disease | 0 to 4 | 0.0 |
Acute | Pelvic inflammatory disease | 5 to 9 | 0.0 |
Acute | Pelvic inflammatory disease | 10 to 14 | 0.0 |
Acute | Pelvic inflammatory disease | 15 to 19 | 0.5 |
Acute | Pelvic inflammatory disease | 20 to 24 | 0.7 |
Acute | Pelvic inflammatory disease | 25 to 29 | 0.6 |
Acute | Pelvic inflammatory disease | 30 to 34 | 0.6 |
Acute | Pelvic inflammatory disease | 35 to 39 | 0.5 |
Acute | Pelvic inflammatory disease | 40 to 44 | 0.4 |
Acute | Pelvic inflammatory disease | 45 to 49 | 0.3 |
Acute | Pelvic inflammatory disease | 50 to 54 | 0.2 |
Acute | Pelvic inflammatory disease | 55 to 59 | 0.1 |
Acute | Pelvic inflammatory disease | 60 to 64 | 0.0 |
Acute | Pelvic inflammatory disease | 65 to 69 | 0.0 |
Acute | Pelvic inflammatory disease | 70 to 74 | 0.0 |
Acute | Pelvic inflammatory disease | 75 to 79 | 0.0 |
Acute | Pelvic inflammatory disease | 80 to 84 | 0.0 |
Acute | Pelvic inflammatory disease | 85 plus | 0.0 |
Acute | Perforated/bleeding ulcer | 0 to 4 | 0.0 |
Acute | Perforated/bleeding ulcer | 5 to 9 | 0.0 |
Acute | Perforated/bleeding ulcer | 10 to 14 | 0.0 |
Acute | Perforated/bleeding ulcer | 15 to 19 | 0.0 |
Acute | Perforated/bleeding ulcer | 20 to 24 | 0.0 |
Acute | Perforated/bleeding ulcer | 25 to 29 | 0.1 |
Acute | Perforated/bleeding ulcer | 30 to 34 | 0.1 |
Acute | Perforated/bleeding ulcer | 35 to 39 | 0.1 |
Acute | Perforated/bleeding ulcer | 40 to 44 | 0.1 |
Acute | Perforated/bleeding ulcer | 45 to 49 | 0.2 |
Acute | Perforated/bleeding ulcer | 50 to 54 | 0.2 |
Acute | Perforated/bleeding ulcer | 55 to 59 | 0.3 |
Acute | Perforated/bleeding ulcer | 60 to 64 | 0.4 |
Acute | Perforated/bleeding ulcer | 65 to 69 | 0.5 |
Acute | Perforated/bleeding ulcer | 70 to 74 | 0.6 |
Acute | Perforated/bleeding ulcer | 75 to 79 | 0.9 |
Acute | Perforated/bleeding ulcer | 80 to 84 | 1.4 |
Acute | Perforated/bleeding ulcer | 85 plus | 1.5 |
Acute | Pneumonia (not vaccine-preventable) | 0 to 4 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 5 to 9 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 10 to 14 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 15 to 19 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 20 to 24 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 25 to 29 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 30 to 34 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 35 to 39 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 40 to 44 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 45 to 49 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 50 to 54 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 55 to 59 | 0.1 |
Acute | Pneumonia (not vaccine-preventable) | 60 to 64 | 0.1 |
Acute | Pneumonia (not vaccine-preventable) | 65 to 69 | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | 70 to 74 | 0.1 |
Acute | Pneumonia (not vaccine-preventable) | 75 to 79 | 0.2 |
Acute | Pneumonia (not vaccine-preventable) | 80 to 84 | 0.2 |
Acute | Pneumonia (not vaccine-preventable) | 85 plus | 0.4 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 0 to 4 | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 5 to 9 | 0.0 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 10 to 14 | 0.0 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 15 to 19 | 0.0 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 20 to 24 | 0.0 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 25 to 29 | 0.0 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 30 to 34 | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 35 to 39 | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 40 to 44 | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 45 to 49 | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 50 to 54 | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 55 to 59 | 0.2 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 60 to 64 | 0.3 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 65 to 69 | 0.3 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 70 to 74 | 0.2 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 75 to 79 | 0.3 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 80 to 84 | 0.4 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | 85 plus | 0.6 |
Chronic | Rheumatic heart diseases | 0 to 4 | 0.0 |
Chronic | Rheumatic heart diseases | 5 to 9 | 0.1 |
Chronic | Rheumatic heart diseases | 10 to 14 | 0.1 |
Chronic | Rheumatic heart diseases | 15 to 19 | 0.1 |
Chronic | Rheumatic heart diseases | 20 to 24 | 0.1 |
Chronic | Rheumatic heart diseases | 25 to 29 | 0.1 |
Chronic | Rheumatic heart diseases | 30 to 34 | 0.1 |
Chronic | Rheumatic heart diseases | 35 to 39 | 0.1 |
Chronic | Rheumatic heart diseases | 40 to 44 | 0.1 |
Chronic | Rheumatic heart diseases | 45 to 49 | 0.1 |
Chronic | Rheumatic heart diseases | 50 to 54 | 0.2 |
Chronic | Rheumatic heart diseases | 55 to 59 | 0.1 |
Chronic | Rheumatic heart diseases | 60 to 64 | 0.3 |
Chronic | Rheumatic heart diseases | 65 to 69 | 0.6 |
Chronic | Rheumatic heart diseases | 70 to 74 | 0.8 |
Chronic | Rheumatic heart diseases | 75 to 79 | 1.6 |
Chronic | Rheumatic heart diseases | 80 to 84 | 1.4 |
Chronic | Rheumatic heart diseases | 85 plus | 0.9 |
NA | Total potentially preventable hospitalisations | 0 to 4 | 33.4 |
NA | Total potentially preventable hospitalisations | 5 to 9 | 19.4 |
NA | Total potentially preventable hospitalisations | 10 to 14 | 9.6 |
NA | Total potentially preventable hospitalisations | 15 to 19 | 16.7 |
NA | Total potentially preventable hospitalisations | 20 to 24 | 18.1 |
NA | Total potentially preventable hospitalisations | 25 to 29 | 15.7 |
NA | Total potentially preventable hospitalisations | 30 to 34 | 15.5 |
NA | Total potentially preventable hospitalisations | 35 to 39 | 17.8 |
NA | Total potentially preventable hospitalisations | 40 to 44 | 19.6 |
NA | Total potentially preventable hospitalisations | 45 to 49 | 22.1 |
NA | Total potentially preventable hospitalisations | 50 to 54 | 26.1 |
NA | Total potentially preventable hospitalisations | 55 to 59 | 30.5 |
NA | Total potentially preventable hospitalisations | 60 to 64 | 38.2 |
NA | Total potentially preventable hospitalisations | 65 to 69 | 50.2 |
NA | Total potentially preventable hospitalisations | 70 to 74 | 67.8 |
NA | Total potentially preventable hospitalisations | 75 to 79 | 97.6 |
NA | Total potentially preventable hospitalisations | 80 to 84 | 132.9 |
NA | Total potentially preventable hospitalisations | 85 plus | 192.6 |
Acute | Urinary tract infections, including pyelonephritis | 0 to 4 | 3.6 |
Acute | Urinary tract infections, including pyelonephritis | 5 to 9 | 1.0 |
Acute | Urinary tract infections, including pyelonephritis | 10 to 14 | 0.6 |
Acute | Urinary tract infections, including pyelonephritis | 15 to 19 | 2.8 |
Acute | Urinary tract infections, including pyelonephritis | 20 to 24 | 3.4 |
Acute | Urinary tract infections, including pyelonephritis | 25 to 29 | 2.7 |
Acute | Urinary tract infections, including pyelonephritis | 30 to 34 | 2.3 |
Acute | Urinary tract infections, including pyelonephritis | 35 to 39 | 2.1 |
Acute | Urinary tract infections, including pyelonephritis | 40 to 44 | 2.3 |
Acute | Urinary tract infections, including pyelonephritis | 45 to 49 | 2.4 |
Acute | Urinary tract infections, including pyelonephritis | 50 to 54 | 2.7 |
Acute | Urinary tract infections, including pyelonephritis | 55 to 59 | 3.4 |
Acute | Urinary tract infections, including pyelonephritis | 60 to 64 | 4.5 |
Acute | Urinary tract infections, including pyelonephritis | 65 to 69 | 5.8 |
Acute | Urinary tract infections, including pyelonephritis | 70 to 74 | 9.2 |
Acute | Urinary tract infections, including pyelonephritis | 75 to 79 | 14.6 |
Acute | Urinary tract infections, including pyelonephritis | 80 to 84 | 23.0 |
Acute | Urinary tract infections, including pyelonephritis | 85 plus | 41.5 |
Vaccine preventable | Total vaccine preventable | 0 to 4 | 0.3 |
Vaccine preventable | Total vaccine preventable | 5 to 9 | 0.0 |
Vaccine preventable | Total vaccine preventable | 10 to 14 | 0.0 |
Vaccine preventable | Total vaccine preventable | 15 to 19 | 0.1 |
Vaccine preventable | Total vaccine preventable | 20 to 24 | 0.2 |
Vaccine preventable | Total vaccine preventable | 25 to 29 | 0.4 |
Vaccine preventable | Total vaccine preventable | 30 to 34 | 0.7 |
Vaccine preventable | Total vaccine preventable | 35 to 39 | 0.9 |
Vaccine preventable | Total vaccine preventable | 40 to 44 | 1.1 |
Vaccine preventable | Total vaccine preventable | 45 to 49 | 1.2 |
Vaccine preventable | Total vaccine preventable | 50 to 54 | 1.4 |
Vaccine preventable | Total vaccine preventable | 55 to 59 | 1.8 |
Vaccine preventable | Total vaccine preventable | 60 to 64 | 2.0 |
Vaccine preventable | Total vaccine preventable | 65 to 69 | 2.3 |
Vaccine preventable | Total vaccine preventable | 70 to 74 | 1.8 |
Vaccine preventable | Total vaccine preventable | 75 to 79 | 1.8 |
Vaccine preventable | Total vaccine preventable | 80 to 84 | 1.4 |
Vaccine preventable | Total vaccine preventable | 85 plus | 1.5 |
Remoteness and socioeconomic differences
Because PPHs are considered a proxy measure of healthcare availability outside of hospital settings, regional variations may indicate inequitable primary healthcare access and variations in modifiable risk factors.5,6 Disparities represent an opportunity to improve the health of many Queenslanders.
In 2020–21:
- The standardised rate for total PPHs in remote and very remote areas was double that in major cities and this was evident for each PPH category (Figure 3). Total PPHs were 27.5 per 1,000 persons in major cities compared to 55.7 per 1,000 persons in remote or very remote areas.
- Similar disparities occurred by socioeconomic status—the standardised rate for total PPHs in the most socioeconomically disadvantaged areas was 86.7% higher than in the most advantaged areas (40.6 compared to 21.7 per 1,000 persons, respectively).
Figure 3: Selected potentially preventable hospitalisations by remoteness and socioeconomic status for Queensland residents, 2020–21
Area classification | Area category | Condition | Type | Rate per 1,000 |
---|---|---|---|---|
SEIFA | Most disadvantaged | Total acute | Crude Rate | 23.1 |
SEIFA | Most disadvantaged | Total acute | Age Standardised Rate | 21.8 |
SEIFA | Q2 | Total acute | Crude Rate | 19.5 |
SEIFA | Q2 | Total acute | Age Standardised Rate | 18.3 |
SEIFA | Q3 | Total acute | Crude Rate | 16.1 |
SEIFA | Q3 | Total acute | Age Standardised Rate | 15.6 |
SEIFA | Q4 | Total acute | Crude Rate | 14.6 |
SEIFA | Q4 | Total acute | Age Standardised Rate | 14.3 |
SEIFA | Most advantaged | Total acute | Crude Rate | 12.4 |
SEIFA | Most advantaged | Total acute | Age Standardised Rate | 12.5 |
SEIFA | Most disadvantaged | Total chronic | Crude Rate | 21.7 |
SEIFA | Most disadvantaged | Total chronic | Age Standardised Rate | 17.6 |
SEIFA | Q2 | Total chronic | Crude Rate | 17.8 |
SEIFA | Q2 | Total chronic | Age Standardised Rate | 14.3 |
SEIFA | Q3 | Total chronic | Crude Rate | 13.1 |
SEIFA | Q3 | Total chronic | Age Standardised Rate | 11.9 |
SEIFA | Q4 | Total chronic | Crude Rate | 12.0 |
SEIFA | Q4 | Total chronic | Age Standardised Rate | 11.0 |
SEIFA | Most advantaged | Total chronic | Crude Rate | 8.9 |
SEIFA | Most advantaged | Total chronic | Age Standardised Rate | 8.6 |
SEIFA | Most disadvantaged | Total potentially preventable hospitalisations | Crude Rate | 46.1 |
SEIFA | Most disadvantaged | Total potentially preventable hospitalisations | Age Standardised Rate | 40.6 |
SEIFA | Q2 | Total potentially preventable hospitalisations | Crude Rate | 38.1 |
SEIFA | Q2 | Total potentially preventable hospitalisations | Age Standardised Rate | 33.3 |
SEIFA | Q3 | Total potentially preventable hospitalisations | Crude Rate | 29.9 |
SEIFA | Q3 | Total potentially preventable hospitalisations | Age Standardised Rate | 28.1 |
SEIFA | Q4 | Total potentially preventable hospitalisations | Crude Rate | 27.3 |
SEIFA | Q4 | Total potentially preventable hospitalisations | Age Standardised Rate | 26.0 |
SEIFA | Most advantaged | Total potentially preventable hospitalisations | Crude Rate | 21.9 |
SEIFA | Most advantaged | Total potentially preventable hospitalisations | Age Standardised Rate | 21.7 |
SEIFA | Most disadvantaged | Total vaccine preventable | Crude Rate | 1.5 |
SEIFA | Most disadvantaged | Total vaccine preventable | Age Standardised Rate | 1.4 |
SEIFA | Q2 | Total vaccine preventable | Crude Rate | 0.9 |
SEIFA | Q2 | Total vaccine preventable | Age Standardised Rate | 0.8 |
SEIFA | Q3 | Total vaccine preventable | Crude Rate | 0.7 |
SEIFA | Q3 | Total vaccine preventable | Age Standardised Rate | 0.6 |
SEIFA | Q4 | Total vaccine preventable | Crude Rate | 0.9 |
SEIFA | Q4 | Total vaccine preventable | Age Standardised Rate | 0.8 |
SEIFA | Most advantaged | Total vaccine preventable | Crude Rate | 0.7 |
SEIFA | Most advantaged | Total vaccine preventable | Age Standardised Rate | 0.7 |
Remoteness | Major cities | Total acute | Crude Rate | 15.4 |
Remoteness | Major cities | Total acute | Age Standardised Rate | 15.0 |
Remoteness | Inner regional | Total acute | Crude Rate | 19.5 |
Remoteness | Inner regional | Total acute | Age Standardised Rate | 18.2 |
Remoteness | Outer regional | Total acute | Crude Rate | 19.4 |
Remoteness | Outer regional | Total acute | Age Standardised Rate | 18.6 |
Remoteness | Remote and very remote | Total acute | Crude Rate | 28.6 |
Remoteness | Remote and very remote | Total acute | Age Standardised Rate | 28.6 |
Remoteness | Major cities | Total chronic | Crude Rate | 12.9 |
Remoteness | Major cities | Total chronic | Age Standardised Rate | 11.7 |
Remoteness | Inner regional | Total chronic | Crude Rate | 18.3 |
Remoteness | Inner regional | Total chronic | Age Standardised Rate | 14.0 |
Remoteness | Outer regional | Total chronic | Crude Rate | 15.3 |
Remoteness | Outer regional | Total chronic | Age Standardised Rate | 13.4 |
Remoteness | Remote and very remote | Total chronic | Crude Rate | 24.2 |
Remoteness | Remote and very remote | Total chronic | Age Standardised Rate | 24.7 |
Remoteness | Major cities | Total potentially preventable hospitalisations | Crude Rate | 29.2 |
Remoteness | Major cities | Total potentially preventable hospitalisations | Age Standardised Rate | 27.5 |
Remoteness | Inner regional | Total potentially preventable hospitalisations | Crude Rate | 38.3 |
Remoteness | Inner regional | Total potentially preventable hospitalisations | Age Standardised Rate | 32.7 |
Remoteness | Outer regional | Total potentially preventable hospitalisations | Crude Rate | 35.4 |
Remoteness | Outer regional | Total potentially preventable hospitalisations | Age Standardised Rate | 32.7 |
Remoteness | Remote and very remote | Total potentially preventable hospitalisations | Crude Rate | 55.1 |
Remoteness | Remote and very remote | Total potentially preventable hospitalisations | Age Standardised Rate | 55.7 |
Remoteness | Major cities | Total vaccine preventable | Crude Rate | 1.0 |
Remoteness | Major cities | Total vaccine preventable | Age Standardised Rate | 0.9 |
Remoteness | Inner regional | Total vaccine preventable | Crude Rate | 0.6 |
Remoteness | Inner regional | Total vaccine preventable | Age Standardised Rate | 0.5 |
Remoteness | Outer regional | Total vaccine preventable | Crude Rate | 0.9 |
Remoteness | Outer regional | Total vaccine preventable | Age Standardised Rate | 0.9 |
Remoteness | Remote and very remote | Total vaccine preventable | Crude Rate | 2.9 |
Remoteness | Remote and very remote | Total vaccine preventable | Age Standardised Rate | 2.9 |
Potentially preventable hospitalisations by specific condition
The leading PPH condition in 2020–21 was urinary tract infections, including pyelonephritis, followed by dental conditions and cellulitis, which are acute PPHs.
The conditions with the highest standardised rate differed by sex:
- males—cellulitis, followed by dental conditions and diabetes complications
- females—urinary tract infections, dental conditions and iron deficiency anaemia (Figure 4).
Some effects of COVID-19 public health measures and changes in hospitalisation admission practices were evident in 2020–21. For example, hospitalisations for pneumonia (non-vaccine and vaccine preventable) decreased whereas hospitalisation for dental conditions increased (Supplemental Figure S1 under Additional information).
Figure 4: Selected potentially preventable hospitalisations by specific conditions for Queensland residents, 2020–21
PPH category | Condition | Sex | Type | Rate per 1,000 |
---|---|---|---|---|
Chronic | Angina | Females | Crude Rate | 1.0 |
Chronic | Angina | Females | Age Standardised Rate | 0.8 |
Chronic | Angina | Males | Crude Rate | 1.6 |
Chronic | Angina | Males | Age Standardised Rate | 1.4 |
Chronic | Angina | Persons | Crude Rate | 1.3 |
Chronic | Angina | Persons | Age Standardised Rate | 1.1 |
Chronic | Asthma | Females | Crude Rate | 1.3 |
Chronic | Asthma | Females | Age Standardised Rate | 1.3 |
Chronic | Asthma | Males | Crude Rate | 0.9 |
Chronic | Asthma | Males | Age Standardised Rate | 0.9 |
Chronic | Asthma | Persons | Crude Rate | 1.1 |
Chronic | Asthma | Persons | Age Standardised Rate | 1.1 |
Chronic | Bronchiectasis | Females | Crude Rate | 0.6 |
Chronic | Bronchiectasis | Females | Age Standardised Rate | 0.5 |
Chronic | Bronchiectasis | Males | Crude Rate | 0.3 |
Chronic | Bronchiectasis | Males | Age Standardised Rate | 0.3 |
Chronic | Bronchiectasis | Persons | Crude Rate | 0.4 |
Chronic | Bronchiectasis | Persons | Age Standardised Rate | 0.4 |
Chronic | COPD | Females | Crude Rate | 2.5 |
Chronic | COPD | Females | Age Standardised Rate | 2.0 |
Chronic | COPD | Males | Crude Rate | 2.7 |
Chronic | COPD | Males | Age Standardised Rate | 2.3 |
Chronic | COPD | Persons | Crude Rate | 2.6 |
Chronic | COPD | Persons | Age Standardised Rate | 2.1 |
Acute | Cellulitis | Females | Crude Rate | 3.2 |
Acute | Cellulitis | Females | Age Standardised Rate | 2.9 |
Acute | Cellulitis | Males | Crude Rate | 4.3 |
Acute | Cellulitis | Males | Age Standardised Rate | 4.1 |
Acute | Cellulitis | Persons | Crude Rate | 3.8 |
Acute | Cellulitis | Persons | Age Standardised Rate | 3.5 |
Chronic | Congestive cardiac failure | Females | Crude Rate | 2.5 |
Chronic | Congestive cardiac failure | Females | Age Standardised Rate | 1.9 |
Chronic | Congestive cardiac failure | Males | Crude Rate | 2.9 |
Chronic | Congestive cardiac failure | Males | Age Standardised Rate | 2.6 |
Chronic | Congestive cardiac failure | Persons | Crude Rate | 2.7 |
Chronic | Congestive cardiac failure | Persons | Age Standardised Rate | 2.2 |
Acute | Convulsions and epilepsy | Females | Crude Rate | 1.7 |
Acute | Convulsions and epilepsy | Females | Age Standardised Rate | 1.7 |
Acute | Convulsions and epilepsy | Males | Crude Rate | 2.1 |
Acute | Convulsions and epilepsy | Males | Age Standardised Rate | 2.1 |
Acute | Convulsions and epilepsy | Persons | Crude Rate | 1.9 |
Acute | Convulsions and epilepsy | Persons | Age Standardised Rate | 1.9 |
Acute | Dental conditions | Females | Crude Rate | 3.9 |
Acute | Dental conditions | Females | Age Standardised Rate | 3.9 |
Acute | Dental conditions | Males | Crude Rate | 3.5 |
Acute | Dental conditions | Males | Age Standardised Rate | 3.5 |
Acute | Dental conditions | Persons | Crude Rate | 3.7 |
Acute | Dental conditions | Persons | Age Standardised Rate | 3.7 |
Chronic | Diabetes complications | Females | Crude Rate | 2.0 |
Chronic | Diabetes complications | Females | Age Standardised Rate | 1.9 |
Chronic | Diabetes complications | Males | Crude Rate | 3.1 |
Chronic | Diabetes complications | Males | Age Standardised Rate | 2.8 |
Chronic | Diabetes complications | Persons | Crude Rate | 2.6 |
Chronic | Diabetes complications | Persons | Age Standardised Rate | 2.3 |
Acute | Ear, nose and throat infections | Females | Crude Rate | 2.0 |
Acute | Ear, nose and throat infections | Females | Age Standardised Rate | 2.1 |
Acute | Ear, nose and throat infections | Males | Crude Rate | 2.0 |
Acute | Ear, nose and throat infections | Males | Age Standardised Rate | 2.0 |
Acute | Ear, nose and throat infections | Persons | Crude Rate | 2.0 |
Acute | Ear, nose and throat infections | Persons | Age Standardised Rate | 2.1 |
Acute | Eclampsia | Females | Crude Rate | 0.0 |
Acute | Eclampsia | Females | Age Standardised Rate | 0.0 |
Acute | Eclampsia | Males | Crude Rate | 0.0 |
Acute | Eclampsia | Persons | Crude Rate | 0.0 |
Acute | Eclampsia | Persons | Age Standardised Rate | 0.0 |
Acute | Gangrene | Females | Crude Rate | 0.6 |
Acute | Gangrene | Females | Age Standardised Rate | 0.5 |
Acute | Gangrene | Males | Crude Rate | 0.8 |
Acute | Gangrene | Males | Age Standardised Rate | 0.8 |
Acute | Gangrene | Persons | Crude Rate | 0.7 |
Acute | Gangrene | Persons | Age Standardised Rate | 0.6 |
Chronic | Hypertension | Females | Crude Rate | 1.2 |
Chronic | Hypertension | Females | Age Standardised Rate | 0.9 |
Chronic | Hypertension | Males | Crude Rate | 0.6 |
Chronic | Hypertension | Males | Age Standardised Rate | 0.5 |
Chronic | Hypertension | Persons | Crude Rate | 0.9 |
Chronic | Hypertension | Persons | Age Standardised Rate | 0.8 |
Chronic | Iron deficiency anaemia | Females | Crude Rate | 3.4 |
Chronic | Iron deficiency anaemia | Females | Age Standardised Rate | 3.1 |
Chronic | Iron deficiency anaemia | Males | Crude Rate | 1.9 |
Chronic | Iron deficiency anaemia | Males | Age Standardised Rate | 1.7 |
Chronic | Iron deficiency anaemia | Persons | Crude Rate | 2.7 |
Chronic | Iron deficiency anaemia | Persons | Age Standardised Rate | 2.4 |
Chronic | Nutritional deficiencies | Females | Crude Rate | 0.1 |
Chronic | Nutritional deficiencies | Females | Age Standardised Rate | 0.1 |
Chronic | Nutritional deficiencies | Males | Crude Rate | 0.1 |
Chronic | Nutritional deficiencies | Males | Age Standardised Rate | 0.1 |
Chronic | Nutritional deficiencies | Persons | Crude Rate | 0.1 |
Chronic | Nutritional deficiencies | Persons | Age Standardised Rate | 0.1 |
Vaccine preventable | Other vaccine-preventable conditions | Females | Crude Rate | 0.7 |
Vaccine preventable | Other vaccine-preventable conditions | Females | Age Standardised Rate | 0.7 |
Vaccine preventable | Other vaccine-preventable conditions | Males | Crude Rate | 0.9 |
Vaccine preventable | Other vaccine-preventable conditions | Males | Age Standardised Rate | 0.8 |
Vaccine preventable | Other vaccine-preventable conditions | Persons | Crude Rate | 0.8 |
Vaccine preventable | Other vaccine-preventable conditions | Persons | Age Standardised Rate | 0.8 |
Acute | Pelvic inflammatory disease | Females | Crude Rate | 0.5 |
Acute | Pelvic inflammatory disease | Females | Age Standardised Rate | 0.5 |
Acute | Pelvic inflammatory disease | Males | Crude Rate | 0.0 |
Acute | Pelvic inflammatory disease | Persons | Crude Rate | 0.3 |
Acute | Pelvic inflammatory disease | Persons | Age Standardised Rate | 0.3 |
Acute | Perforated/bleeding ulcer | Females | Crude Rate | 0.2 |
Acute | Perforated/bleeding ulcer | Females | Age Standardised Rate | 0.1 |
Acute | Perforated/bleeding ulcer | Males | Crude Rate | 0.3 |
Acute | Perforated/bleeding ulcer | Males | Age Standardised Rate | 0.3 |
Acute | Perforated/bleeding ulcer | Persons | Crude Rate | 0.2 |
Acute | Perforated/bleeding ulcer | Persons | Age Standardised Rate | 0.2 |
Acute | Pneumonia (not vaccine-preventable) | Females | Crude Rate | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | Females | Age Standardised Rate | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | Males | Crude Rate | 0.1 |
Acute | Pneumonia (not vaccine-preventable) | Males | Age Standardised Rate | 0.1 |
Acute | Pneumonia (not vaccine-preventable) | Persons | Crude Rate | 0.0 |
Acute | Pneumonia (not vaccine-preventable) | Persons | Age Standardised Rate | 0.0 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | Females | Crude Rate | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | Females | Age Standardised Rate | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | Males | Crude Rate | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | Males | Age Standardised Rate | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | Persons | Crude Rate | 0.1 |
Vaccine preventable | Pneumonia and influenza (vaccine-preventable) | Persons | Age Standardised Rate | 0.1 |
Chronic | Rheumatic heart diseases | Females | Crude Rate | 0.2 |
Chronic | Rheumatic heart diseases | Females | Age Standardised Rate | 0.2 |
Chronic | Rheumatic heart diseases | Males | Crude Rate | 0.3 |
Chronic | Rheumatic heart diseases | Males | Age Standardised Rate | 0.2 |
Chronic | Rheumatic heart diseases | Persons | Crude Rate | 0.2 |
Chronic | Rheumatic heart diseases | Persons | Age Standardised Rate | 0.2 |
Acute | Urinary tract infections, including pyelonephritis | Females | Crude Rate | 6.1 |
Acute | Urinary tract infections, including pyelonephritis | Females | Age Standardised Rate | 5.5 |
Acute | Urinary tract infections, including pyelonephritis | Males | Crude Rate | 2.9 |
Acute | Urinary tract infections, including pyelonephritis | Males | Age Standardised Rate | 2.6 |
Acute | Urinary tract infections, including pyelonephritis | Persons | Crude Rate | 4.5 |
Acute | Urinary tract infections, including pyelonephritis | Persons | Age Standardised Rate | 4.1 |
Trends
While standardised rates for PPHs steadily increased from 2010–11 to 2017–18, recent declines were largely driven by decreases for chronic conditions such as angina, asthma, and COPD. PPHs for acute conditions, however, have increased with some variability due to COVID-19.
Vaccine preventable PPHs saw a large decline in 2020–21 due in large part to reduced flu-related hospitalisations from COVID-19 public safety measures (Figure 5 and Supplemental Figure S1 under Additional information).
Figure 5: Trends in selected potentially preventable hospitalisations by sex for Queensland residents
Year | Condition | Sex | Type | ASR per 1,000 |
---|---|---|---|---|
2010-11 | Total acute | Females | Crude Rate | 13.3 |
2010-11 | Total acute | Females | Age Standardised Rate | 13.0 |
2010-11 | Total acute | Males | Crude Rate | 12.2 |
2010-11 | Total acute | Males | Age Standardised Rate | 12.4 |
2010-11 | Total acute | Persons | Crude Rate | 12.8 |
2010-11 | Total acute | Persons | Age Standardised Rate | 12.7 |
2011-12 | Total acute | Females | Crude Rate | 13.4 |
2011-12 | Total acute | Females | Age Standardised Rate | 13.0 |
2011-12 | Total acute | Males | Crude Rate | 12.3 |
2011-12 | Total acute | Males | Age Standardised Rate | 12.4 |
2011-12 | Total acute | Persons | Crude Rate | 12.8 |
2011-12 | Total acute | Persons | Age Standardised Rate | 12.7 |
2012-13 | Total acute | Females | Crude Rate | 14.6 |
2012-13 | Total acute | Females | Age Standardised Rate | 14.2 |
2012-13 | Total acute | Males | Crude Rate | 12.9 |
2012-13 | Total acute | Males | Age Standardised Rate | 13.0 |
2012-13 | Total acute | Persons | Crude Rate | 13.8 |
2012-13 | Total acute | Persons | Age Standardised Rate | 13.6 |
2013-14 | Total acute | Females | Crude Rate | 15.1 |
2013-14 | Total acute | Females | Age Standardised Rate | 14.6 |
2013-14 | Total acute | Males | Crude Rate | 13.4 |
2013-14 | Total acute | Males | Age Standardised Rate | 13.5 |
2013-14 | Total acute | Persons | Crude Rate | 14.3 |
2013-14 | Total acute | Persons | Age Standardised Rate | 14.0 |
2014-15 | Total acute | Females | Crude Rate | 16.2 |
2014-15 | Total acute | Females | Age Standardised Rate | 15.6 |
2014-15 | Total acute | Males | Crude Rate | 13.9 |
2014-15 | Total acute | Males | Age Standardised Rate | 13.9 |
2014-15 | Total acute | Persons | Crude Rate | 15.0 |
2014-15 | Total acute | Persons | Age Standardised Rate | 14.7 |
2015-16 | Total acute | Females | Crude Rate | 16.5 |
2015-16 | Total acute | Females | Age Standardised Rate | 15.9 |
2015-16 | Total acute | Males | Crude Rate | 14.5 |
2015-16 | Total acute | Males | Age Standardised Rate | 14.4 |
2015-16 | Total acute | Persons | Crude Rate | 15.5 |
2015-16 | Total acute | Persons | Age Standardised Rate | 15.1 |
2016-17 | Total acute | Females | Crude Rate | 17.2 |
2016-17 | Total acute | Females | Age Standardised Rate | 16.5 |
2016-17 | Total acute | Males | Crude Rate | 15.0 |
2016-17 | Total acute | Males | Age Standardised Rate | 14.8 |
2016-17 | Total acute | Persons | Crude Rate | 16.1 |
2016-17 | Total acute | Persons | Age Standardised Rate | 15.6 |
2017-18 | Total acute | Females | Crude Rate | 17.7 |
2017-18 | Total acute | Females | Age Standardised Rate | 17.0 |
2017-18 | Total acute | Males | Crude Rate | 15.3 |
2017-18 | Total acute | Males | Age Standardised Rate | 15.1 |
2017-18 | Total acute | Persons | Crude Rate | 16.5 |
2017-18 | Total acute | Persons | Age Standardised Rate | 16.0 |
2018-19 | Total acute | Females | Crude Rate | 17.9 |
2018-19 | Total acute | Females | Age Standardised Rate | 17.2 |
2018-19 | Total acute | Males | Crude Rate | 15.9 |
2018-19 | Total acute | Males | Age Standardised Rate | 15.6 |
2018-19 | Total acute | Persons | Crude Rate | 16.9 |
2018-19 | Total acute | Persons | Age Standardised Rate | 16.4 |
2019-20 | Total acute | Females | Crude Rate | 17.2 |
2019-20 | Total acute | Females | Age Standardised Rate | 16.5 |
2019-20 | Total acute | Males | Crude Rate | 15.0 |
2019-20 | Total acute | Males | Age Standardised Rate | 14.7 |
2019-20 | Total acute | Persons | Crude Rate | 16.1 |
2019-20 | Total acute | Persons | Age Standardised Rate | 15.6 |
2020-21 | Total acute | Females | Crude Rate | 18.2 |
2020-21 | Total acute | Females | Age Standardised Rate | 17.4 |
2020-21 | Total acute | Males | Crude Rate | 15.8 |
2020-21 | Total acute | Males | Age Standardised Rate | 15.3 |
2020-21 | Total acute | Persons | Crude Rate | 17.0 |
2020-21 | Total acute | Persons | Age Standardised Rate | 16.3 |
2010-11 | Total chronic | Females | Crude Rate | 12.3 |
2010-11 | Total chronic | Females | Age Standardised Rate | 11.5 |
2010-11 | Total chronic | Males | Crude Rate | 12.7 |
2010-11 | Total chronic | Males | Age Standardised Rate | 13.3 |
2010-11 | Total chronic | Persons | Crude Rate | 12.5 |
2010-11 | Total chronic | Persons | Age Standardised Rate | 12.3 |
2011-12 | Total chronic | Females | Crude Rate | 12.5 |
2011-12 | Total chronic | Females | Age Standardised Rate | 11.6 |
2011-12 | Total chronic | Males | Crude Rate | 13.1 |
2011-12 | Total chronic | Males | Age Standardised Rate | 13.6 |
2011-12 | Total chronic | Persons | Crude Rate | 12.8 |
2011-12 | Total chronic | Persons | Age Standardised Rate | 12.4 |
2012-13 | Total chronic | Females | Crude Rate | 13.0 |
2012-13 | Total chronic | Females | Age Standardised Rate | 12.0 |
2012-13 | Total chronic | Males | Crude Rate | 13.5 |
2012-13 | Total chronic | Males | Age Standardised Rate | 13.8 |
2012-13 | Total chronic | Persons | Crude Rate | 13.3 |
2012-13 | Total chronic | Persons | Age Standardised Rate | 12.7 |
2013-14 | Total chronic | Females | Crude Rate | 12.9 |
2013-14 | Total chronic | Females | Age Standardised Rate | 11.8 |
2013-14 | Total chronic | Males | Crude Rate | 13.2 |
2013-14 | Total chronic | Males | Age Standardised Rate | 13.3 |
2013-14 | Total chronic | Persons | Crude Rate | 13.1 |
2013-14 | Total chronic | Persons | Age Standardised Rate | 12.4 |
2014-15 | Total chronic | Females | Crude Rate | 14.1 |
2014-15 | Total chronic | Females | Age Standardised Rate | 12.7 |
2014-15 | Total chronic | Males | Crude Rate | 13.8 |
2014-15 | Total chronic | Males | Age Standardised Rate | 13.7 |
2014-15 | Total chronic | Persons | Crude Rate | 13.9 |
2014-15 | Total chronic | Persons | Age Standardised Rate | 13.1 |
2015-16 | Total chronic | Females | Crude Rate | 15.3 |
2015-16 | Total chronic | Females | Age Standardised Rate | 13.8 |
2015-16 | Total chronic | Males | Crude Rate | 14.5 |
2015-16 | Total chronic | Males | Age Standardised Rate | 14.1 |
2015-16 | Total chronic | Persons | Crude Rate | 14.9 |
2015-16 | Total chronic | Persons | Age Standardised Rate | 13.9 |
2016-17 | Total chronic | Females | Crude Rate | 16.1 |
2016-17 | Total chronic | Females | Age Standardised Rate | 14.3 |
2016-17 | Total chronic | Males | Crude Rate | 15.0 |
2016-17 | Total chronic | Males | Age Standardised Rate | 14.4 |
2016-17 | Total chronic | Persons | Crude Rate | 15.5 |
2016-17 | Total chronic | Persons | Age Standardised Rate | 14.3 |
2017-18 | Total chronic | Females | Crude Rate | 16.5 |
2017-18 | Total chronic | Females | Age Standardised Rate | 14.6 |
2017-18 | Total chronic | Males | Crude Rate | 15.5 |
2017-18 | Total chronic | Males | Age Standardised Rate | 14.7 |
2017-18 | Total chronic | Persons | Crude Rate | 16.0 |
2017-18 | Total chronic | Persons | Age Standardised Rate | 14.6 |
2018-19 | Total chronic | Females | Crude Rate | 16.2 |
2018-19 | Total chronic | Females | Age Standardised Rate | 14.1 |
2018-19 | Total chronic | Males | Crude Rate | 15.2 |
2018-19 | Total chronic | Males | Age Standardised Rate | 14.1 |
2018-19 | Total chronic | Persons | Crude Rate | 15.7 |
2018-19 | Total chronic | Persons | Age Standardised Rate | 14.1 |
2019-20 | Total chronic | Females | Crude Rate | 15.7 |
2019-20 | Total chronic | Females | Age Standardised Rate | 13.6 |
2019-20 | Total chronic | Males | Crude Rate | 14.6 |
2019-20 | Total chronic | Males | Age Standardised Rate | 13.3 |
2019-20 | Total chronic | Persons | Crude Rate | 15.1 |
2019-20 | Total chronic | Persons | Age Standardised Rate | 13.4 |
2020-21 | Total chronic | Females | Crude Rate | 14.8 |
2020-21 | Total chronic | Females | Age Standardised Rate | 12.6 |
2020-21 | Total chronic | Males | Crude Rate | 14.3 |
2020-21 | Total chronic | Males | Age Standardised Rate | 12.8 |
2020-21 | Total chronic | Persons | Crude Rate | 14.6 |
2020-21 | Total chronic | Persons | Age Standardised Rate | 12.7 |
2010-11 | Total potentially preventable hospitalisations | Females | Crude Rate | 26.2 |
2010-11 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 25.1 |
2010-11 | Total potentially preventable hospitalisations | Males | Crude Rate | 25.5 |
2010-11 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 26.3 |
2010-11 | Total potentially preventable hospitalisations | Persons | Crude Rate | 25.9 |
2010-11 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 25.5 |
2011-12 | Total potentially preventable hospitalisations | Females | Crude Rate | 26.6 |
2011-12 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 25.2 |
2011-12 | Total potentially preventable hospitalisations | Males | Crude Rate | 26.2 |
2011-12 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 26.7 |
2011-12 | Total potentially preventable hospitalisations | Persons | Crude Rate | 26.4 |
2011-12 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 25.8 |
2012-13 | Total potentially preventable hospitalisations | Females | Crude Rate | 28.6 |
2012-13 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 27.1 |
2012-13 | Total potentially preventable hospitalisations | Males | Crude Rate | 27.4 |
2012-13 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 27.8 |
2012-13 | Total potentially preventable hospitalisations | Persons | Crude Rate | 28.0 |
2012-13 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 27.3 |
2013-14 | Total potentially preventable hospitalisations | Females | Crude Rate | 28.9 |
2013-14 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 27.3 |
2013-14 | Total potentially preventable hospitalisations | Males | Crude Rate | 27.8 |
2013-14 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 27.9 |
2013-14 | Total potentially preventable hospitalisations | Persons | Crude Rate | 28.4 |
2013-14 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 27.4 |
2014-15 | Total potentially preventable hospitalisations | Females | Crude Rate | 31.9 |
2014-15 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 29.9 |
2014-15 | Total potentially preventable hospitalisations | Males | Crude Rate | 29.4 |
2014-15 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 29.2 |
2014-15 | Total potentially preventable hospitalisations | Persons | Crude Rate | 30.7 |
2014-15 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 29.5 |
2015-16 | Total potentially preventable hospitalisations | Females | Crude Rate | 34.0 |
2015-16 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 31.7 |
2015-16 | Total potentially preventable hospitalisations | Males | Crude Rate | 31.3 |
2015-16 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 30.8 |
2015-16 | Total potentially preventable hospitalisations | Persons | Crude Rate | 32.6 |
2015-16 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 31.1 |
2016-17 | Total potentially preventable hospitalisations | Females | Crude Rate | 35.3 |
2016-17 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 32.7 |
2016-17 | Total potentially preventable hospitalisations | Males | Crude Rate | 32.2 |
2016-17 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 31.3 |
2016-17 | Total potentially preventable hospitalisations | Persons | Crude Rate | 33.8 |
2016-17 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 31.9 |
2017-18 | Total potentially preventable hospitalisations | Females | Crude Rate | 37.7 |
2017-18 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 34.7 |
2017-18 | Total potentially preventable hospitalisations | Males | Crude Rate | 34.2 |
2017-18 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 32.9 |
2017-18 | Total potentially preventable hospitalisations | Persons | Crude Rate | 35.9 |
2017-18 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 33.7 |
2018-19 | Total potentially preventable hospitalisations | Females | Crude Rate | 36.4 |
2018-19 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 33.5 |
2018-19 | Total potentially preventable hospitalisations | Males | Crude Rate | 33.5 |
2018-19 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 32.0 |
2018-19 | Total potentially preventable hospitalisations | Persons | Crude Rate | 35.0 |
2018-19 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 32.7 |
2019-20 | Total potentially preventable hospitalisations | Females | Crude Rate | 35.8 |
2019-20 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 32.6 |
2019-20 | Total potentially preventable hospitalisations | Males | Crude Rate | 32.2 |
2019-20 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 30.4 |
2019-20 | Total potentially preventable hospitalisations | Persons | Crude Rate | 34.0 |
2019-20 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 31.5 |
2020-21 | Total potentially preventable hospitalisations | Females | Crude Rate | 33.7 |
2020-21 | Total potentially preventable hospitalisations | Females | Age Standardised Rate | 30.7 |
2020-21 | Total potentially preventable hospitalisations | Males | Crude Rate | 31.0 |
2020-21 | Total potentially preventable hospitalisations | Males | Age Standardised Rate | 28.9 |
2020-21 | Total potentially preventable hospitalisations | Persons | Crude Rate | 32.4 |
2020-21 | Total potentially preventable hospitalisations | Persons | Age Standardised Rate | 29.8 |
2010-11 | Total vaccine preventable | Females | Crude Rate | 0.7 |
2010-11 | Total vaccine preventable | Females | Age Standardised Rate | 0.6 |
2010-11 | Total vaccine preventable | Males | Crude Rate | 0.8 |
2010-11 | Total vaccine preventable | Males | Age Standardised Rate | 0.8 |
2010-11 | Total vaccine preventable | Persons | Crude Rate | 0.7 |
2010-11 | Total vaccine preventable | Persons | Age Standardised Rate | 0.7 |
2011-12 | Total vaccine preventable | Females | Crude Rate | 0.7 |
2011-12 | Total vaccine preventable | Females | Age Standardised Rate | 0.7 |
2011-12 | Total vaccine preventable | Males | Crude Rate | 0.9 |
2011-12 | Total vaccine preventable | Males | Age Standardised Rate | 0.9 |
2011-12 | Total vaccine preventable | Persons | Crude Rate | 0.8 |
2011-12 | Total vaccine preventable | Persons | Age Standardised Rate | 0.8 |
2012-13 | Total vaccine preventable | Females | Crude Rate | 1.1 |
2012-13 | Total vaccine preventable | Females | Age Standardised Rate | 1.1 |
2012-13 | Total vaccine preventable | Males | Crude Rate | 1.2 |
2012-13 | Total vaccine preventable | Males | Age Standardised Rate | 1.2 |
2012-13 | Total vaccine preventable | Persons | Crude Rate | 1.1 |
2012-13 | Total vaccine preventable | Persons | Age Standardised Rate | 1.1 |
2013-14 | Total vaccine preventable | Females | Crude Rate | 1.1 |
2013-14 | Total vaccine preventable | Females | Age Standardised Rate | 1.0 |
2013-14 | Total vaccine preventable | Males | Crude Rate | 1.3 |
2013-14 | Total vaccine preventable | Males | Age Standardised Rate | 1.2 |
2013-14 | Total vaccine preventable | Persons | Crude Rate | 1.2 |
2013-14 | Total vaccine preventable | Persons | Age Standardised Rate | 1.1 |
2014-15 | Total vaccine preventable | Females | Crude Rate | 1.9 |
2014-15 | Total vaccine preventable | Females | Age Standardised Rate | 1.8 |
2014-15 | Total vaccine preventable | Males | Crude Rate | 2.0 |
2014-15 | Total vaccine preventable | Males | Age Standardised Rate | 1.9 |
2014-15 | Total vaccine preventable | Persons | Crude Rate | 2.0 |
2014-15 | Total vaccine preventable | Persons | Age Standardised Rate | 1.9 |
2015-16 | Total vaccine preventable | Females | Crude Rate | 2.4 |
2015-16 | Total vaccine preventable | Females | Age Standardised Rate | 2.3 |
2015-16 | Total vaccine preventable | Males | Crude Rate | 2.7 |
2015-16 | Total vaccine preventable | Males | Age Standardised Rate | 2.6 |
2015-16 | Total vaccine preventable | Persons | Crude Rate | 2.6 |
2015-16 | Total vaccine preventable | Persons | Age Standardised Rate | 2.4 |
2016-17 | Total vaccine preventable | Females | Crude Rate | 2.4 |
2016-17 | Total vaccine preventable | Females | Age Standardised Rate | 2.2 |
2016-17 | Total vaccine preventable | Males | Crude Rate | 2.5 |
2016-17 | Total vaccine preventable | Males | Age Standardised Rate | 2.4 |
2016-17 | Total vaccine preventable | Persons | Crude Rate | 2.5 |
2016-17 | Total vaccine preventable | Persons | Age Standardised Rate | 2.3 |
2017-18 | Total vaccine preventable | Females | Crude Rate | 4.0 |
2017-18 | Total vaccine preventable | Females | Age Standardised Rate | 3.6 |
2017-18 | Total vaccine preventable | Males | Crude Rate | 3.8 |
2017-18 | Total vaccine preventable | Males | Age Standardised Rate | 3.6 |
2017-18 | Total vaccine preventable | Persons | Crude Rate | 3.9 |
2017-18 | Total vaccine preventable | Persons | Age Standardised Rate | 3.6 |
2018-19 | Total vaccine preventable | Females | Crude Rate | 2.6 |
2018-19 | Total vaccine preventable | Females | Age Standardised Rate | 2.4 |
2018-19 | Total vaccine preventable | Males | Crude Rate | 2.7 |
2018-19 | Total vaccine preventable | Males | Age Standardised Rate | 2.6 |
2018-19 | Total vaccine preventable | Persons | Crude Rate | 2.7 |
2018-19 | Total vaccine preventable | Persons | Age Standardised Rate | 2.5 |
2019-20 | Total vaccine preventable | Females | Crude Rate | 3.2 |
2019-20 | Total vaccine preventable | Females | Age Standardised Rate | 2.9 |
2019-20 | Total vaccine preventable | Males | Crude Rate | 2.9 |
2019-20 | Total vaccine preventable | Males | Age Standardised Rate | 2.8 |
2019-20 | Total vaccine preventable | Persons | Crude Rate | 3.1 |
2019-20 | Total vaccine preventable | Persons | Age Standardised Rate | 2.8 |
2020-21 | Total vaccine preventable | Females | Crude Rate | 0.9 |
2020-21 | Total vaccine preventable | Females | Age Standardised Rate | 0.8 |
2020-21 | Total vaccine preventable | Males | Crude Rate | 1.0 |
2020-21 | Total vaccine preventable | Males | Age Standardised Rate | 0.9 |
2020-21 | Total vaccine preventable | Persons | Crude Rate | 0.9 |
2020-21 | Total vaccine preventable | Persons | Age Standardised Rate | 0.9 |
Additional information
Data and statistics
The figure below provides more detailed information for PPHs.
Supplemental Figure S1: Trends in selected potentially preventable hospitalisations in Queensland
Section technical notes
Where presented, ratios were calculated using higher precision estimates than those that are displayed within the report.
Data reported in this section were sourced from the Queensland Hospital Admitted Patient Data Collection (QHAPDC). Individual records in the QHAPDC are episode-based, meaning that multiple episodes from the same person will be counted in a reporting period.
Separations for interstate residents, public psychiatric hospitals, and those flagged as unqualified newborns, organ donors or boarders are excluded. Records from 47 previously declared hospitals are excluded.
For definition on selected potentially preventable hospitalisations, refer to coding standards in METEOR on the Australian Institute of Health website.
Unless otherwise stated, age-standardised rates were calculated by standardising to 2001 Australian standard population.
References
- Australian Institute of Health and Welfare,. 2021. National Healthcare Agreement: PI 18–Selected potentially preventable hospitalisations, 2022. Accessed: 20 September 2022.
- Falster M. & Jorm L. 2017. A guide to the potentially preventable hospitalisations indicator in Australia.
- Queensland Health. 2023. Queensland Hospital Admitted Patient Data Collection (QHAPDC). Accessed: 12 November 2022.
- Australian Government Productivity Commission. 2022. Report on Government Services 2022. Accessed: 24 October 2022.
- Australian Institute of Health and Welfare. 2019. Potentially preventable hospitalisations in Australia by age groups and small geographic areas, 2017–18. Accessed: 14 September 2022.
- Australian Institute of Health and Welfare,. 2020. Disparities in potentially preventable hospitalisations across Australia, 2012-13 to 2017-18. Accessed: 20 September 2022.